Developing cell culture-derived pandemic vaccines

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 1, 2010, Pages 21-30

  Barrett, P Noel ^a   Portsmouth, Daniel ^a   Ehrlich, Hartmut J ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Cell culture; H1N1; H5N1; Influenza; Pandemic; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BACULOVIRUS VECTOR; CELPAVAN; CELTURA; FLUBLOK; INFLUENZA VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; CELL STRAIN; CLINICAL TRIAL; CULTURE TECHNIQUE; DRUG EFFICACY; DRUG MANUFACTURE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INSECT CELL; MAMMAL CELL; NONHUMAN; PANDEMIC; REVIEW; SERODIAGNOSIS; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VERO CELL; VIRUS STRAIN;

ANIMALS; CELL CULTURE TECHNIQUES; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; POULTRY; WORLD HEALTH;

AVIAN INFLUENZA VIRUS; MAMMALIA; ORTHOMYXOVIRIDAE; SUIDAE;

EID: 76749161782     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Seasonal influenza: World Health Organization, Copenhagen, Denmark (2009). www.euro.who.int/influenza/20080618-1
2. Hampson AW, Mackenzie JS: The influenza viruses. Med J Aust (2006) 185(10 Suppl):S39-S43.
3. Poland GA, Jacobson RM, Targonski PV: Avian and pandemic influenza: An overview. Vaccine (2007) 25(16):3057-3061.
4. Johnson NP, Mueller J: Updating the accounts: Global mortality of the 1918-1920 'Spanish' influenza pandemic. Bull Hist Med (2002) 76(1):105-115.
5. Luke CJ, Subbarao K: Vaccines for pandemic influenza. Emerg Infect Dis (2006) 12(1):66-72.
6. Michaelis M, Doerr HW, Cinatl J Jr: Of chickens and men: Avian influenza in humans. Curr Mol Med (2009) 9(2):131-151.
7. Neumann G, Noda T, Kawaoka Y: Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature (2009) 459(7249):931-939.
8. Recommended composition of influenza virus vaccines for use in the 2010 southern hemisphere influenza season: World Health Organization, Geneva, Switzerland (2009). www.who.int/csr/disease/influenza/200909-Recommendation.pdf
9. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO: World Health Organization, Geneva, Switzerland (2009). www.who.int/csr/ disease/avian-influenza/country/cases-table-2009-09-24/en/ index. html
10. Neumann G, Kawaoka Y: Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis (2006) 12(6):881-886.
11. Chang SC, Cheng YY, Shih SR: Avian influenza virus: The threat of a pandemic. Chang Gung Med J (2006) 29(2): 130-134.
12. Sorrell EM, Ramirez-Nieto GC, Gomez-Osorio IG, Perez DR: Genesis of pandemic influenza. Cytogenet Genome Res (2007) 117(1-4):394-402.
13. Michaelis M, Doerr HW, Cinatl J Jr: Novel swine-origin influenza A virus in humans: Another pandemic knocking at the door. Med Microbiol Immunol (2009) 198(3):175-183.
14. Michaelis M, Doerr HW, Cinatl J Jr: An influenza A H1N1 virus revival - Pandemic H1N1/09 virus. Infection (2009): doi:10.1007/s15010-009-9181-5.
15. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG: Stockpiling prepandemic influenza vaccines: A new cornerstone of pandemic preparedness plans. Lancet Infect Dis (2008) 8(10):650-658.
16. Palache B, Krause R: Progress with human H5N1 vaccines: A perspective from industry. Expert Rev Vaccines (2009) 8(4): 391-400.
17. Hampson AW: Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singapore (2008) 37(6):510-517.
18. Leroux-Roels I, Leroux-Roels G: Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines (2009) 8(4):401-423.
19. Collin N, de Radiguès X: Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine (2009) 27(38):5184-5186.
20. World population prospects: The 2008 revision: World Health Organization, Geneva, Switzerland (2009). www.who.int/pmnch/topics/2008-populationstats/en/
21. Rowe PM: Pandemic influenza (un)preparedness described. Lancet (1995) 346:1699.
22. Hardy CT, Young SA, Webster RG, Naeve CW, Owens RJ: Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. Virology (1995) 211(1):302-306.
23. Robertson JS, Bootman JS, Newman R, Oxford JS, Daniels RS, Webster RG, Schild GC: Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A (H1N1) virus. Virology (1987) 160(1):31-37.
24. Schild GC, Oxford JS, de Jong JC, Webster RG: Evidence for host-cell selection of influenza virus antigenic variants. Nature (1983) 303(5919):706-709.
25. Robertson JS, Nicolson C, Major D, Robertson EW, Wood JM: The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J Gen Virol (1993) 74(Pt 10):2047-2051.
26. Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG: Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stand (1999) 98:39-51.
27. Katz JM, Webster RG: Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis (1989) 160(2):191-198.
28. Barrett PN, Mundt W, Kistner O, Howard MK: Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines. Expert Rev Vaccines (2009) 8(5):607-618.
29. Cells products safety. Background papers from the WHO Study Group on Biologicals. Geneva, 18-19 Nov. 1986. Dev Biol Stand (1987) 68:1-81.
30. Goldstein MA, Tauraso NM, Orr HC: Evaluation of three cell culture systems as substrates for influenza virus assay. Appl Microbiol (1970) 19(4):580-582.
31. Lazarowitz SG, Choppin PW: Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology (1975) 68(2):440-454.
32. Yasamura Y, Kawakita Y: Study of SV40 in tissue culture. Nippon Rinsho (1963) 21:1201-1205.
33. Furesz J, Fanok A, Contreras G, Becker B: Tumorigenicity testing of various cell substrates for production of biologicals. Dev Biol Stand (1989) 70:233-243.
34. Horaud F: Absence of viral sequences in the WHO-Vero cell bank. A collaborative study. Dev Biol Stand (1992) 76: 43-46.
35. Levenbook IS, Petricciani JC, Elisberg BL: Tumorigenicity of Vero cells. J Biol Stand (1984) 12(4):391-398.
36. Montagnon BJ, Vincent-Falquet JC, Saluzzo JF: Experience with Vero cells at Pasteur Merieux Connaught. Dev Biol Stand (1999) 98:137-140.
37. Vincent-Falquet JC, Peyron L, Souvras M, Moulin JC, Tektoff J, Patet J: Qualification of working cell banks for the Vero cell line to produce licensed human vaccines. Dev Biol Stand (1989) 70:153-156.
38. Vidor E, Meschievitz C, Plotkin S: Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J (1997) 16(3):312-322.
39. Govorkova EA, Murti G, Meignier B, de Taisne C, Webster RG: African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol (1996) 70(8):5519-5524.
40. Kaverin NV, Webster RG: Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity. J Virol (1995) 69(4):2700-2703.
41. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F: Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine (1998) 16(9-10): 960-968.
42. Kistner O, Howard MK, Spruth M, Wodal W, Bruhl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I et al: Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine (2007) 25(32):6028-6036.
43. Spruth M, Kistner O, Savidis-Dacho H, Hitter E, Crowe B, Gerencer M, Bruhl P, Grillberger L, Reiter M, Tauer C, Mundt W et al: A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine (2006) 24(5):652-661.
44. van Wezel AL, van Steenis G, Hannik CA, Cohen H: New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Stand (1978) 41:159-168.
45. Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Low-Baselli A, Vartian N et al: A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med (2008) 358(24): 2573-2584.
46. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC: Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet (2006) 367(9523):1657-1664. (Pubitemid 43744370)
47. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med (2006) 354(13): 1343-1351.
48. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A: Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by toll-like receptor signalling. PLoS Pathog (2008) 4(8):e1000138.
49. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M et al: Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: A phase I randomised controlled trial. Lancet (2006) 368(9540):991-997.
50. Stephenson I: H5N1 vaccines: How prepared are we for a pandemic? Lancet (2006) 368(9540):965-966.
51. Ehrlich HJ, Müller M, Fritsch S, Zeitlinger M, Berezuk G, Löw-Baselli A, van der Velden MV, Pöllabauer EM, Maritsch F, Pavlova BG, Tambyah PA et al: A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis (2009) 200(7):1113-1118.
52. Sabarth N, Howard MK, Savidis-Dacho H, van Maurik A, Barrett PN, Kistner O: Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine (2010) 28(3):650-656.
53. Cohen J, Enserink M: Swine flu. After delays, WHO agrees: The 2009 pandemic has begun. Science (2009) 324(5934): 1496-1497.
54. Baxter Intenational Inc: Baxter receives european commission approval for CELVAPAN H1N1 pandemic influenza vaccine. Press Release (2009): October 07.
55. Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, Morokutti A, Shurygina AP, Nakowitsch S, Ruthsatz T, Kiefmann B, König U et al: Preclinical evaluation of a replication-deficient intranasal NS1 H5N1 influenza vaccine. PLoS One (2009) 4(6):e5984.
56. Desmyter J, Melnick JL, Rawls WE: Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol (1968) 2(10):955-961.
57. Cox RJ, Brokstad KA, Ogra P: Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol (2004) 59(1):1-15.
58. Tosh PK, Boyce TG, Poland GA: Flu myths: Dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc (2008) 83(1):77-84.
59. Harper SA, Fukuda K, Cox NJ, Bridges CB: Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2003) 52(RR-13):1-8.
60. Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, Brühl P, Gerencer M, Crowe BA, Shuo S, Hong W, Tan YJ et al: Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J Virol (2009) 83(10):5192-5203.
61. Gaush CR, Hard WL, Smith TF: Characterization of an established line of canine kidney cells (MDCK). Proc Soc Exp Biol Med (1966) 122(3):931-935.
62. Madin SH, Darby NB Jr: Established kidney cell lines of normal adult bovine and ovine origin. Proc Soc Exp Biol Med (1958) 98(3):574-576.
63. Halperin SA, Nestruck AC, Eastwood BJ: Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine (1998) 16(13):1331-1335.
64. Palache AM, Brands R, van Scharrenburg GJ: Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis (1997) 176(Suppl 1):S20-S23.
65. Palache AM, Scheepers HS, de Regt, V, van Ewijk P, Baljet M, Brands R, van Scharrenburg GJ: Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev Biol Stand (1999) 98:115-125.
66. Percheson PB, Trepanier P, Dugre R, Mabrouk T: A phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line. Dev Biol Stand (1999) 98:127-132.
67. Gregersen JP: A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine (2008) 26(26):3297-3304.
68. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A: Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential phase I and phase II clinical trial. Vaccine (2009) 27(5):786-791.
69. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ: Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: Comparison of safety, reactogenicity, and immunogenicity. J Infect Dis (2009) 200(6):849-857.
70. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A: Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis (2009) 200(6):841-848.
71. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I: Trial of influenza A (H1N1) 2009 monovalent MF59 - adjuvanted vaccine. N Engl J Med (2009) 361(25): 2424-2435.
72. Novartis AG: Novartis receives regulatory approval in Germany for Celtura® , a cell culture-based influenza A(H1N1) pandemic vaccine. Press Release (2009): November 05.
73. Background summary for the September 25, 2008, VRBPAC meeting: Use of MDCK cells for manufacture of live attenuated influenza vaccines: Food and Drug Administration, Silver Spring, MD, USA (2008). www.fda.gov/ ohrms/dockets/ac/08/ briefing/2008-4384B1-3.pdf
74. Vaccines and related biological products advisory committee: November 16-17 2005: Food and Drug Administration, Silver Spring, MD, USA (2005). www.fda.gov/ohrms/dockets/ac/cber05.html#VaccinesandRelatedBi ological
75. Use of cell lines for the production of influenza virus vaccines: An appraisal of technical, manufacturing, and regulatory considerations: World Health Organization, Geneva, Switzerland (2007). www.who.int/vaccine-research/ diseases/ influenza/WHO-Flu-Cell-Substrate-Version3.pdf
76. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D et al: New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther (1998) 9(13):1909-1917.
77. Lewis JA, Brown EL, Duncan PA: Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev Biol (Basel) (2006) 123:165-176.
78. Koudstaal W, Hartgroves L, Havenga M, Legastelois I, Ophorst C, Sieuwerts M, Zuijdgeest D, Vogels R, Custers J, de Boer-Luijtze E, de Leeuw O et al: Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine (2009) 27(19):2588-2593.
79. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F: The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine (2001) 19(17-19):2716-2721.
80. Ledwith BJ, Lanning CL, Gumprecht LA, Anderson CA, Coleman JB, Gatto NT, Balasubramanian G, Farris GM, Kemp RK, Harper LB, Barnum AB et al: Tumorigenicity assessments of PER.C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line. Dev Biol (Basel) (2006) 123:251-263.
81. Tables on the Clinical trials of pandemic influenza prototype vaccines: World Health Organization, Geneva, Switzerland (2009). www.who.int/vaccine- research/diseases/influenza/flu-trials-tables/ en/index.html
82. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, Donatelli I et al: A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine (2009) 27(13):1889-1897.
83. He F, Madhan S, Kwang J: Baculovirus vector as a delivery vehicle for influenza vaccines. Expert Rev Vaccines (2009) 8(4):455-467.
84. Cox MM: Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther (2008) 10(1):56-61.
85. McPherson CE: Development of a novel recombinant influenza vaccine in insect cells. Biologicals (2008) 36(6): 350-353.
86. Brooks SA: Appropriate glycosylation of recombinant proteins for human use: Implications of choice of expression system. Mol Biotechnol (2004) 28(3):241-255.
87. Yin J, Li G, Ren X, Herrler G: Select what you need: A comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J Biotechnol (2007) 127(3):335-347.
88. Cox MM: Commercial production in insect cells: One company's perspective. BioProcess Intl (2004) 2 (Sup 2): 34-38.
89. Cox MM, Hollister JR: FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals (2009) 37(3):182-189.
90. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine (2001) 19(13-14):1732-1737.
91. Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ: Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis (2008) 198(5):635-641.
92. Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, Quan FS, Chen LM, Donis RO, Compans RW: Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One (2009) 4(3):e4667.
93. Kang SM, Song JM, Quan FS, Compans RW: Influenza vaccines based on virus-like particles. Virus Res (2009) 143(2):140-146.
94. Pushko P, Tumpey TM, Van HN, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA: Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine (2007) 25(21):4283-4290.
95. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G: Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine (2005) 23(50): 5751-5759.
96. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM: Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One (2008) 3(1):e1501.
97. Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM: H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine (2008) 26(42):5393-5399.
98. Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J: Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology (2008) 380(2):412-420.
99. Doherty PC, Turner SJ, Webby RG, Thomas PG: Influenza and the challenge for immunology. Nat Immunol (2006) 7(5): 449-455.
100. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC: T cell responses are better correlates of vaccine protection in the elderly. J Immunol (2006) 176(10):6333-6339.
101. McMichael AJ, Gotch F, Cullen P, Askonas B, Webster RG: The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol (1981) 43(2):276-284.
102. Nicholson KG, Tyrrell DA, Harrison P, Potter CW, Jennings R, Clark A, Schild GC, Wood JM, Yetts R, Seagroatt V, Huggins A et al: Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: Serological responses and clinical reactions. J Biol Stand (1979) 7(2): 123-136.
103. Geeraedts F, Bungener L, Pool J, Ter VW, Wilschut J, Huckriede A: Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi Viruses (2008) 2(2):41-51.
104. Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den BH, Schijns V, Betbeder D, Vromans H, Jiskoot W: Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: Effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine (2008) 26(51):6555-6563.
105. Hovden AO, Cox RJ, Haaheim LR: Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol (2005) 62(1):36-44.
106. Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI: Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine (2006) 24(47-48):6859-6866.
107. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG: Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis (2006) 194(2):159-167.
108. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC: Cell-mediated protection in influenza infection. Emerg Infect Dis (2006) 12(1):48-54.
109. Rimmelzwaan GF, McElhaney JE: Correlates of protection: Novel generations of influenza vaccines. Vaccine (2008) 26 (Suppl 4):D41-D44.